En español
NIDA

Menu

NIDA Notes Articles: Medication Development
NIDA Notes Category Graphic

Neuropeptide Promotes Behaviors Tied to Addiction and Overeating

July 2011
Reports on several studies implicating a certain neuropeptide (a signaling molecule) in fostering addition and overeating and discusses implications for addiction treatment.
NIDA Notes Category Graphic

New Tools and Strategies to Bolster Behavioral Therapy

October 2010

Reports on research investigating whether certain medications might strengthen patients' understanding and memory retention.
NIDA Notes Category Graphic

New Vaccines Are Being Developed Against Addiction and Relapse

December 2008

Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
NIDA Notes Category Graphic

NIDA Announces Avant-Garde Medication Development Awards

March 2012
Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.
NIDA Notes Category Graphic

NIDA Appoints New Director of the Intramural Research Program

December 2010
Announces NIDA’s new director of its intramural research program, Antonello Bonci, M.D., a leading researcher in neuropsychopharmacology.

NIDA Notes Category Graphic

Oxycodone Vaccine Passes Early Tests

May 2013

A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.
NIDA Notes Category Graphic

Potential Pain Medication Targets Peripheral Nerves

September 2012

Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.
NIDA Notes Category Graphic

Q&A: Dr. David Thomas

November 2012

NIDA Program Officer Dr. David Thomas speaks about the intertwined problems of pain and prescription opioid abuse, as well as the research supported by NIDA and the National Institutes of Health to address these problems.
NIDA Notes Category Graphic

Selenium Shows Promise as an Adjunct Therapy for HIV

December 2008

Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
NIDA Notes Category Graphic

Test Substance Attenuates Signs of Cocaine Withdrawal in Rats

December 2009

Reports on several drugs that may ward off depression and anxiety, common withdrawal symptoms from cocaine, based on an animal study.

Pages

NIDA Notes

Categories

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics

Attention

Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at

USA.gov

Looking for Treatment?

Use the SAMHSA Treatment Locator or 1-800-662-HELP.

Helpline open during government shutdown